Overview:
Apellis Pharmaceuticals (APLS) surged 136% in premarket trading on March 31, 2026, reaching $40.35 after Biogen agreed to acquire the company for $41 per share in cash — a deal valued at approximately $5.6 billion. The offer represents a 140% premium to APLS's last close of $17.09, with additional contingent value rights worth up to $4 per share tied to SYFOVRE global net sales milestones. Session volume exceeded 33 million shares, roughly 12 times APLS's average daily volume of 2.78 million, un
Market data analysis for PreMarket Daily readers.
This article is published by PreMarket Daily for informational and educational purposes only. Nothing here constitutes financial advice, investment recommendations, or an offer to buy or sell any securities. Always consult a qualified financial professional before making investment decisions.